New drug targets Hard-to-Treat prostate cancer in early trial

NCT ID NCT03792841

Terminated Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called acapatamab in 212 men with advanced prostate cancer that had stopped responding to standard hormone therapy and chemotherapy. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety and find the best dose, but the study was stopped early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

BC Cancer Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
City of Hope National Medical Center

Duarte, California, 91010, United States
City of Hope at Long Beach Elm

Long Beach, California, 90813, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
El Camino Hospital

Campbell, California, 95008, United States
Emory University

Atlanta, Georgia, 30322, United States
Erasmus Medisch Centrum

Rotterdam, 3015 GD, Netherlands
Indiana University

Indianapolis, Indiana, 46202, United States
Institut Gustave Roussy

Villejuif, 94805, France
Krankenhaus der Barmherzigen Brueder Wien

Vienna, 1020, Austria
Landeskrankenhaus Salzburg

Salzburg, 5020, Austria
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation

Taoyuan, 33305, Taiwan
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
National Cancer Centre Singapore

Singapore, 169610, Singapore
National University Hospital

Singapore, 119074, Singapore
Ordensklinikum Linz Elisabethinen

Linz, 4020, Austria
Peter MacCallum Cancer Centre

Parkville, Victoria, 3050, Australia
Scientia Clinical Research Ltd

Randwick, New South Wales, 2031, Australia
Tulane Medical Center

New Orleans, Louisiana, 70112, United States
Universitaetsklinikum Allgemeines Krankenhaus Wien

Vienna, 1090, Austria
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
Universite Catholique de Louvain Cliniques Universitaires Saint Luc

Brussels, 1200, Belgium
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Washington University

St Louis, Missouri, 63110, United States
Weill Cornell Medical College

New York, New York, 10065, United States
Yokohama City University Medical Center

Yokohama, Kanagawa, 232-0024, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.